Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Frilabiol Joint is an oral nutraceutical product marketed by **FRiLAB**, a Swiss pharmaceutical distribution and marketing company. It is part of the Frilabiol range of dietary supplements, which are designed to support various physiological functions including immunity, digestion, and sleep. Frilabiol Joint is specifically formulated to promote joint health, maintain cartilage integrity, and support overall mobility. The product typically functions as a combination supplement containing key structural components of joint tissue, such as glucosamine and chondroitin sulfate. These ingredients serve as precursors for the synthesis of glycosaminoglycans and proteoglycans, which are essential for the elasticity and shock-absorbing properties of articular cartilage. It is marketed as an over-the-counter (OTC) food supplement rather than a prescription pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Frilabiol Joint.